Advances in Human Embryonic Stem Cells-Based Therapy for Leukemia
DOI:
https://doi.org/10.54097/03jhxe92Keywords:
Human embryonic stem cells, Leukemia, Stem cells therapy.Abstract
Leukemia refers to a malignant clonal disease triggered by hematopoietic stem cells (HSCs). The leukemia cells are at a standstill at different phases of cell development because of the self-renewal enhancement and differentiation disorder. In the bone marrow and other hematopoietic tissues, leukemia cells proliferate and accumulate rapidly, inhibiting normal hematopoiesis and infiltrating other organs and tissues. Among current clinical treatments, though hematopoietic stem cell transplantation (HSCT) serves as the optimal therapeutic choice for leukemia currently, it faces challenges such as difficulties in donor matching and high risks of complications. Human embryonic stem cells (hESCs), derived from the inner cell mass of embryos, have unlimited self-renewal and multi-directional differentiation potential. These cells exhibit notable value in basic research and disease modeling. hESC-derived HSCs can proliferate at a rapid rate and exhibit strong self-renewal ability. These unique biological traits offer a promising approach for leukemia therapy. However, clinical translation of hESCs still faces severe challenges such as tumorigenicity and low differentiation efficiency. This review summarizes the research progress of hESCs in leukemia treatment, providing a reference for future studies.
Downloads
References
[1] Whiteley, A. E., Price, T. T., Cantelli, G., & Sipkins, D. A. (2021). Leukaemia: a model metastatic disease. Nature reviews. Cancer, 21 (7), 461–475.
[2] Ivanovs, A., Rybtsov, S., Anderson, R. A., & Medvinsky, A. (2020). Vast Self-Renewal Potential of Human AGM Region HSCs Dramatically Declines in the Umbilical Cord Blood. Stem cell reports, 15 (4), 811–816.
[3] Dupont, G., Yilmaz, E., Loukas, M., Macchi, V., De Caro, R., & Tubbs, R. S. (2019). Human embryonic stem cells: Distinct molecular personalities and applications in regenerative medicine. Clinical anatomy (New York, N.Y.), 32 (3), 354–360.
[4] Xie, H., Zhao, S., & Liu, S. (2018). Aging of Human Adult Stem Cells. Advances in experimental medicine and biology, 1086, 105–115.
[5] Choong, C., & Rao, M. S. (2007). Human embryonic stem cells. Neurosurgery clinics of North America, 18 (1), 1–vii.
[6] Rath, A., Mishra, A., Ferreira, V. D., Hu, C., Omerza, G., Kelly, K., Hesse, A., Reddi, H. V., Grady, J. P., & Heinen, C. D. (2019). Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells. Human mutation, 40 (11), 2044–2056.
[7] Mavers, M., & Bertaina, A. (2018). High-Risk Leukemia: Past, Present, and Future Role of NK Cells. Journal of immunology research, 2018, 1586905.
[8] Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009). Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood, 113 (24), 6094–6101.
[9] Dessie, G., Derbew Molla, M., Shibabaw, T., & Ayelign, B. (2020). Role of Stem-Cell Transplantation in Leukemia Treatment. Stem cells and cloning: advances and applications, 13, 67–77.
[10] Nguyen, H. T., Geens, M., & Spits, C. (2013). Genetic and epigenetic instability in human pluripotent stem cells. Human reproduction update, 19 (2), 187–205.
[11] Slukvin I. I. (2013). Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. Blood, 122 (25), 4035–4046.
[12] Tang, C., Lee, A. S., Volkmer, J. P., Sahoo, D., Nag, D., Mosley, A. R., Inlay, M. A., Ardehali, R., Chavez, S. L., Pera, R. R., Behr, B., Wu, J. C., Weissman, I. L., & Drukker, M. (2011). An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature biotechnology, 29 (9), 829–834.
[13] Sugimura, R., Jha, D. K., Han, A., Soria-Valles, C., da Rocha, E. L., Lu, Y. F., Goettel, J. A., Serrao, E., Rowe, R. G., Malleshaiah, M., Wong, I., Sousa, P., Zhu, T. N., Ditadi, A., Keller, G., Engelman, A. N., Snapper, S. B., Doulatov, S., & Daley, G. Q. (2017). Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature, 545 (7655), 432–438.
[14] Slukvin I. I. (2016). Generating human hematopoietic stem cells in vitro -exploring endothelial to hematopoietic transition as a portal for stemness acquisition. FEBS letters, 590 (22), 4126–4143.
[15] Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., Wagner, R., Lee, G. O., Antosiewicz-Bourget, J., Teng, J. M., & Thomson, J. A. (2011). Chemically defined conditions for human iPSC derivation and culture. Nature methods, 8 (5), 424–429.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
